A Phase 4 interventional study of Placebo and Pantoprazole + Placebo in Functional Dyspepsia, sponsored by Zealand University Hospital. Terminated at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.
Sponsored by Zealand University Hospital · Phase 4, Interventional, and Treatment
Proton pump inhibitors (PPI) have been shown to cause acid reflux related symptoms at withdrawal in healthy volunteers, a phenomenon known as Rebound Acid Hyper Secretion. Whether this also applies for patients with dyspeptic symptoms but without true reflux disease (functional dyspepsia) treated with PPI is unknown. If this is the case, it could lead to an unfortunate long term use of PPI, since the acid rebound renders withdrawal too difficult.
This is a single centre, randomized, double-blinded, placebo-controlled cross over study. Study period is 12 weeks per study subject. Study subjects are referred to the study from General Practitioner (GP) and the gastroenterology department or endoscopy clinic of the investigational centre.
The study population consists of patients who seek their GP because of dyspepsia without alert signs, and whom the GP may consider starting on PPI. Out patients referred to the gastroenterology department or endoscopy clinic of the investigational centre because of dyspepsia without specific exclusion criteria are also invited to participate.
Baseline interview, upper endoscopy and pH monitoring are performed one week before inclusion to exclude patients with GERD. Helicobacter Pylori (Hp.) status is assessed by Helicobacter Urease Test (HUT). Hp. positive subjects without ulcus are not excluded.
Patients with a positive pH monitoring will not be included in the analysis regarding the primary endpoint (Development of GERD) but will be included in the analysis regarding one of the secondary endpoints (Effect of PPI on Functional Dyspepsia).
Study subjects are randomized to either pantoprazol followed by cross over to placebo or to placebo. Escape medication in the form of Gaviscon can be used on demand.
Internet based questionnaires are answered weekly. Questionnaires consist of the Gastrointestinal Symptom rating Scale (GSRS) in combination with items assessing postprandial fullness and items assessing the Montreal Criteria for Gastro Esophageal Reflux Disease (GERD).
Compliance to protocol is assessed at hospital visits every fourth week. At the end of study endoscopy and pH monitoring are repeated.
363 studies on the registry are indexed under Dyspepsia; 51 are open to participants now.
This study's enrollment of 184 is above the median of 87 across 297 interventional studies indexed under Dyspepsia.
Browse Dyspepsia studies →Zealand University Hospital is the lead sponsor of 234 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Symptoms indicating dyspepsia, including:
Exclusion Criteria:
Abnormal pH-monitoring prior to enrolment or at screening (pH \<4 in ≥5.5 % of the time on "worst day" of 48-h monitoring)
Drug: Placebo
PPI followed by cross over to placebo
Drug: Pantoprazole + Placebo
Placebo, one tablet daily for 12 weeks
Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
Development of GERD
Comparison of number of study subjects that develop GERD according to the Montreal definition including endoscopic findings and pH monitoring in weeks 9-12 in the PPI group versus the placebo group.
Time frame: week 9 - 12
Use of escape medication
Difference in use of escape medication in weeks 9 - 12 between PPI- and placebo group
Time frame: Week 9 - 12
Endoscopic findings
Number of study subjects who have esophagitis, peptic stricture or Barrett's esophagus at inclusion without having symptoms of reflux.
Time frame: 0 - 2 weeks before inclusion
pH monitoring
Number of study subject who have an abnormal pH monitoring at inclusion with-out symptoms of reflux
Time frame: 0 - 2 weeks before inclusion
Irritable Bowel Syndrome (IBS)
Number of study subjects with ROME III score indicating IBS at inclusion
Time frame: 0 - 2 weeks before inclusion
Irritable Bowel Syndrome (IBS) and treatment
Difference in symptom scores between study subjects with and without IBS in the PPI- and placebo group in weeks 0 - 12
Time frame: Week 0 - 12
Effect of PPI on Functional Dyspepsia
Number of study subjects in the PPI group versus the placebo group that answer "no discomfort at all" or "slight discomfort" to dyspepsia related questions ("ache/pain in the upper part of the abdomen" and "hunger pains/hollow feeling in the stomach") in week 8.
Time frame: Week 8
Helicobacter Pylori
Difference in symptom score for subject with and without H. Pylori between PPI- and placebo group in weeks 9 - 12.
Time frame: Week 9 - 12
This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zealand University Hospital